Vericel (VCEL) Work In Process (2014 - 2026)
Vericel recorded quarterly Work In Process of $1.5 million in Q1 2026, down 4.86% quarter-over-quarter from $1.6 million in Q4 2025, and down 5.04% year-over-year from $1.6 million in Q1 2025.
Vericel's Work In Process history runs 13 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Work In Process fell 5.04% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 5.04% YoY), while the FY2025 annual figure was $1.6 million, up 0.83% from the prior year.
- Work In Process came in at $1.5 million for Q1 2026 at Vericel, down from $1.6 million in the prior quarter.
- In the past five years, Work In Process ranged from a high of $2.1 million in Q2 2025 to a low of $683000.0 in Q2 2022.
- A 5-year average of $1.3 million and a median of $1.5 million in 2025 frame the typical range for Work In Process.
- Across the five-year window, Work In Process jumped 107.07% in 2024 and dropped 20.76% in 2025, its largest moves.
- Vericel's Work In Process stood at $832000.0 in 2022, then surged by 45.43% to $1.2 million in 2023, then increased by 29.83% to $1.6 million in 2024, then advanced by 0.83% to $1.6 million in 2025, then slipped by 4.86% to $1.5 million in 2026.
- According to Business Quant data, Work In Process over the past three periods registered $1.5 million, $1.6 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Vericel | 1.69 Bn | 1.55 Bn | 49.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.51 Mn |
| Dec 31, 2025 | 1.58 Mn |
| Sep 30, 2025 | 1.47 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Mar 31, 2025 | 1.59 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 1.85 Mn |
| Jun 30, 2024 | 1.79 Mn |
| Mar 31, 2024 | 1.75 Mn |
| Dec 31, 2023 | 1.21 Mn |
| Sep 30, 2023 | 967,000.00 |
| Jun 30, 2023 | 863,000.00 |
| Mar 31, 2023 | 1.04 Mn |
| Dec 31, 2022 | 832,000.00 |
| Sep 30, 2022 | 883,000.00 |
| Jun 30, 2022 | 683,000.00 |
| Mar 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | 644,000.00 |
| Sep 30, 2021 | 976,000.00 |
| Jun 30, 2021 | 625,000.00 |
| Mar 31, 2021 | 884,000.00 |
| Dec 31, 2020 | 537,000.00 |
| Sep 30, 2020 | 771,000.00 |
| Jun 30, 2020 | 513,000.00 |
| Mar 31, 2020 | 617,000.00 |
| Dec 31, 2019 | 541,000.00 |
| Sep 30, 2019 | 976,000.00 |
| Jun 30, 2019 | 596,000.00 |
| Mar 31, 2019 | 687,000.00 |
| Dec 31, 2018 | 638,000.00 |
| Sep 30, 2018 | 456,000.00 |
| Jun 30, 2018 | 377,000.00 |
| Mar 31, 2018 | 342,000.00 |
| Dec 31, 2017 | 226,000.00 |
| Sep 30, 2017 | 279,000.00 |
| Jun 30, 2017 | 250,000.00 |
| Mar 31, 2017 | 225,000.00 |
| Dec 31, 2016 | 257,000.00 |
| Sep 30, 2016 | 373,000.00 |
| Jun 30, 2016 | 276,000.00 |
| Mar 31, 2016 | 232,000.00 |
| Dec 31, 2015 | 131,000.00 |
| Sep 30, 2015 | 202,000.00 |
| Jun 30, 2015 | 231,000.00 |
| Mar 31, 2015 | 800,000.00 |
| Dec 31, 2014 | 458,000.00 |
| Sep 30, 2014 | 433,000.00 |
| Jun 30, 2014 | 582,000.00 |